Filter By Unselect All

Sub Category Unselect See All

Country Unselect See All

France (1)

Companies Unselect See All

Selected Filter(s): Reset All

  • Category
  • Reset
  • Sub Category
  • Reset
  • Country
  • Reset

Oligosaccharides Development

API & Drug Product Development >> API Development >> Oligosaccharides & Polysaccharides

SAIS is an oligosaccharides development service provider offering development services of building blocks to hexa-decamer including strong expertise in analyticals. Their capabilities includes oligosaccharides API CDMO services, and hexa decamer oligosaccharides API development etc.

What are Oligosaccharides & Polysaccharides? Oligosaccharides are carbohydrates, composed of up to twenty monosaccharides linked by glycosydic bonds, widely used in food and pharmaceutical industries. These compounds can be obtained by extraction from natural sources (milk, vegetables, fruits), and by chemical or biotechnological processes. In the last case, chemical structures and composition of the generated oligosaccharides depend on the type and source of enzymes, and on process conditions, including the initial concentration of substrate. These are the basic requirements to consider for Oligosaccharides & Polysaccharides Services. What is the significance of Bioactive Oligosaccharides & Polysaccharides in API development? Plant cell wall polysaccharide composition varies substantially between species, organs and genotypes. Knowledge of the structure and composition of these polysaccharides, accompanied by a suite of well characterized glycosyl hydrolases will be important for the success of lignocellulose biofuels. Current methods used to characterize enzymatically released plant oligosaccharides are relatively slow. A method and software was developed allowing the use of a DNA sequencer to profile oligosaccharides APIs derived from plant cell wall polysaccharides (DNA sequencer-Assisted Saccharide analysis in High throughput, DASH). A new device installed at oligosaccharides & polysaccharides API development service providers which can analyses 96 samples simultaneously by capillary electrophoresis can be used to separate fluorophore derived reducing mono- and oligosaccharides from plant cell walls. Using electrophoresis mobility markers, oligosaccharide mobilities were standardized between experiments to enable reproducible oligosaccharide identification. These mobility markers can be flexibly designed to span the mobilities of Oligosaccharides APIs development under investigation, and they have a fluorescence emission that is distinct from that of the saccharide labelling. Methods for relative and absolute quantitation of oligosaccharides are described. Analysis of a large number of samples is facilitated by the software which was developed in parallel. Use of this method was exemplified by comparing xylan structure and content in Arabidopsis thaliana mutants affected in xylan synthesis. The product profiles of specific xylanases were also compared in order to identify enzymes with unusual oligosaccharide products. Oligosaccharides APIs development of Fructo-oligosaccharides (FOS), galacto- oligosaccharides (GOS) and chito- oligosaccharides (COS) for Polysaccharides CDMO service providers. Moreover, novel oligosaccharides with potential prebiotic activity are currently under investigation. Polysaccharides CDMOs focus mainly on the biotechnological production, Polysaccharides API development and applications of non-natural oligosaccharides in hexa decamer oligosaccharides CDMOs. The market for hexa decamer oligosaccharides development is steadily growing. The carbohydrate drugs CDMOs are increasing in antithrombotics development services, the introduction of antithrombotics CDMOs bioprocessing strategies is required for Polysaccharides CDMO service providers. In this chapter, Oligosaccharides development CROs recent developments in the manufacture of galacto- oligosaccharides (GOS) and fructo-oligosaccharides (FOS). The well-established antithrombotics development services oligosaccharides (OS) provide Oligosaccharides Development services and have excellent technological properties that make their use as food ingredients especially attractive. The biosynthesis of lactose-based Oligosaccharides CDMO services and sucrose-based FOS show similarities in terms of idrabiotaparinux CDMOs and product formation. Both Oligosaccharides CDMO services and carbohydrate drugs CDMOs can be synthesized using whole cells or (partially) purified enzymes in immobilized or free forms. The bio catalysis results in a final product that consists of OS, unreacted disaccharides, and monosaccharides. The Oligosaccharides service providers pose a challenge to manufacturers because an enrichment of OS in Oligosaccharides CDMO service providers adds value to the product. For removing digestible carbohydrates from OS by Polysaccharides development services, a variety of Polysaccharides CDMO services have been investigated, including downstream separation technologies, additional bioconversion steps applying enzymes, and selective fermentation strategies. Oligosaccharides API development services the state-of-the-art manufacturing strategies and Oligosaccharides API CDMO services in bioprocessing technologies that can lead to new possibilities for manufacturing and Oligosaccharides API development service providers. Galacto?Oligosaccharides and Polysaccharides CDMO services: Production, Properties, Applications, and Significance Galacto?oligosaccharides in Polysaccharides CDMO services have now been definitely established as prebiotic ingredients after in vitro and animal and human in vivo studies. Currently, Human milk oligosaccharides by glycoside hydrolases (GH) using lactose as substrate. Converting lactose into GOS by GH results in mixtures containing GOS of different degrees of polymerization (DP), unreacted lactose, and monomeric sugars (glucose and galactose). Recent Oligosaccharides bulk development companies aim at delivering services in Development of Synthetic Oligosaccharide-Based Vaccines. To produce high?GOS?content mixtures, GH should not only have good ability to catalyze the transgalactosylation reaction relative to hydrolysis, but synthetic oligosaccharide-based bacterial vaccines formed relative to the affinity for lactose. In this article, several microbial GH, proposed for the Polysaccharides active drug substance development are organized according to the referred performance indicators. In addition, the Synthetic oligosaccharides strategies for process improvement for the oligosaccharides active drug API development. Besides the differences in purity of oligosaccharide synthesis on large scale, differences in the position of the glycosydic linkages occur in Human milk oligosaccharides, because different enzymes have different regiochemical selectivity. Depending on oligosaccharide composition, GOS products will vary in terms of prebiotic activity, as well as other physiological effects. This review focuses on GOS production from synthesis to purification processes. Physicochemical characteristics, physiological effects, and applications of these prebiotic ingredients are summarized. Regulatory aspects of GOS?containing food products by Fermentation process for the production of Human milk oligosaccharides are also emphasised on the current process of Polysaccharides in Oral Drug Delivery. Find oligosaccharides & polysaccharides API development service providers for polysaccharides and hexa decamer oligosaccharides API development. Search by capability like antithrombotics CDMO services, Oligosaccharides API CDMO services and polysaccharides API CDMO services etc. Synthesis Strategies for Polysaccharides in Oral Drug Delivery It is well known that oligosaccharides can be formed from monosaccharides by the action of mineral acids (chemical synthesis). This process, known as “reversion,” explains the production of oligosaccharides during acidic hydrolysis of lactose. The Oral drug delivery conditions suitable for oligosaccharide production during acidic hydrolysis of lactose and the resulting oligosaccharide structures formed have been well studied. It was reported that there is formation of a complex mixture of disaccharides and trisaccharides, with a variety of linkages with ?? and ??anomeric configurations in Organized polysaccharide fibers, and anhydro?sugars, as a result of this chemical process. Probably due to the lack of product specificity and extreme conditions applied during acidic hydrolysis of lactose, this GOS production process is not used on a large scale. Future Prospects of Functional Oligosaccharides Development Globally Several oligosaccharides such as glycosyl-sucrose, fructo-oligosaccharides, maltooligosaccharides, isomalto-oligosaccharides (branched-oligosaccharides), galacto-oligosaccharides, xylo-oligosaccharides, isomaltulose (palatinose), and lactosucrose are the Oligosaccharides in Drug Discovery. Recent developments in Oligosaccharides in Drug Discovery (industrial enzymology) have series of Development of Oligosaccharides in drug discovery such as beta-1,6 linked gentio-oligosaccharides, linked trehalose, alpha-1,3 linked nigero-oligosaccharides, and branched-cyclodextrins. Some new sweeteners, including trehalose and nigero-oligosaccharides, are being developed as food ingredients with physiologically unique functions such as superoxide dismutase-like activity and immunological activity. The best Oligosaccharides CDMO services utilize the advantages of oligosaccharides such as raffinose, stachyose, and other oligosaccharides mentioned above are now used in beverages, confectionery, bakery products, yogurts, daily products, and infant milk. In 1991, the Japanese government legislated for the services of nothing but the best carbohydrate drugs CDMOs increased more than 50% incorporate oligosaccharides as the functional components. Furthermore, the Ministry of Health, Labor, and Welfare for the best idrabiotaparinux CDMOs published the proposal for a new system for the best antithrombotics CDMOs. Select the best approach to determine High Throughput Glycan Analysis N-linked oligosaccharide mapping is routinely performed as an in-process test for recombinant glycoproteins derived from mammalian cell lines. It is seen that the best antithrombotics CDMOs have complexities associated with processing Asparagine-linked (N-linked) oligosaccharides and the sensitivity of the enzymes involved, to even subtle changes in cell culture conditions during manufacturing. In addition, the best antithrombotics CDMOs use methods of oligosaccharide mapping as a potential component of product lot release is increasingly requested from regulatory agencies for consideration. The most commonly used separation methods for oligosaccharide analysis are HPAEC and normal phase chromatography (NP–HPLC) in Oligosaccharides Development CDMOs. The mobile phases used for these separations are not compatible with online MS characterization. Reverse phase (RP–HPLC) separations have been described previously, and provide superior resolution of species compared to HPAEC and NP–HPLC methods.Oligosaccharides & Polysaccharides Services|API Development|CDMOs, The capabilities of leading API development & Oligosaccharides CDMOs should include, but not be limited to the following: · Corticosteroids · Hormones · Multi-steps chemistry · Opiates and opïoids · Prostaglandins · High active products (taxanes) · Oligosaccharides · Peptides · Oligonucleotides · Biotechnologies · Therapeutic proteins · Monoclonal antibodies · Viral vectors · Plasmids Recent developments in synthetic oligosaccharide-based bacterial vaccines Synthetic advances of top Oligosaccharides contract development CDMOs made possible chemical assembly of complex oligosaccharide fragments of polysaccharide domains on the surface of human pathogenic bacteria used in top Oligosaccharides APIs development CDMOs. These oligosaccharides may be recognized by antibodies raised against high molecular weight, native, polysaccharides. In addition to their antigenicity, synthetic oligosaccharides can also function as haptens in top Polysaccharides API development CDMOs that can elicit not only oligo- but also polysaccharide-specific IgG antibodies for the companies that are among the best Oligosaccharides CDMOs. A major milestone in the development of new generation vaccines was that the best Polysaccharides CDMOs demonstrated that protein conjugates of synthetic fragments of the capsular polysaccharide of Haemophilus influenzae type b are as efficacious in preventing childhood meningitis and top Oligosaccharides Development CDMOs as is the corresponding licensed commercial vaccine containing the bacterial polysaccharide. Polysaccharides are complex long chain carbohydrates which are formed by dehydrate synthesis or polymerisation of more than ten but generally very large number of units called monosaccharides. Oligosaccharides: They are small sized polymers of monosaccharides having 2-6 simple sugars occasionally up to 9-10. Get Oligosaccharide Synthesis services for the development of synthetic oligosaccharide-based vaccine candidates, characterized by the presence of pure and well-defined synthetic oligosaccharide structures in Oligosaccharide CDMOs expertise is expected to meet the requirement of homogeneous and highly reproducible preparations. It is important to know some of the carbohydrate-based drugs and fully synthetic vaccines exploiting the multivalency effect. These constructs are based on the concept that the conjugation of multiple copies of synthetic oligosaccharide antigens to multivalent scaffolds, such as dendrimers, (cyclo)peptides, gold nanoparticles, and calixarenes, raises cooperative interactions between carbohydrates and immune receptors, leading to strong enhancement of the saccharide antigen immunogenicity. Oligosaccharide Synthesis CDMOs use polysaccharides are used as simple filling materials, to increase the solubility and/or bioavailability of the active drug, to ease manufacturing of a dosage form, to achieve a certain release profile from the final formulation or to enhance the stability of the final drug product with the Oligosaccharide development expertise. Oligosaccharides CDMOs working on Natural polysaccharides as multifunctional pharmaceutical excipients Polysaccharide hydrocolloids including mucilages, gums and glucans are abundant in nature and commonly used in large-scale enzymatic synthesis of oligosaccharides. The polysaccharides in Oligosaccharide therapeutics constitute a structurally diverse class of biological macromolecules with a broad range of physicochemical properties which are widely used for Oligosaccharide therapeutics. Polysaccharide (Gums and mucilages) functions as versatile excipients such as Suspending Agent, Emulsifying Agent, Binder, Gelling Agent, Disintegrant in Oligosaccharide Synthesis CDMOs. for pharmaceutical formulations. The polysaccharides can also be modified to form multifunctional pharmaceutical excipients to obtain tailor-made materials for drug delivery systems and thus can compete with the available synthetic excipients. Natural Large-Scale Synthesis of H-Antigen Oligosaccharides are among the most widely used multifunctional pharmaceutical excipients in the formulation of different dosage forms. A number of marine-based polysaccharides, such as agar, alginate, carrageenan, fucoidan, chitosan and hyaluronan are utilized in pharmaceutical dosage form as binders, vehicles, disintegrating agents, gelling agents and drug release sustaining agents. The use of carbohydrate-based drugs is in Oligosaccharides contract development has started. In addition to ‘monosaccharide-inspired’ drugs such as influenza treatment Tamiflu (oseltamivir, Roche), two blockbuster drugs, Acarbose (Bayer) and heparin, stand out. Both oligosaccharides in top hexa decamer oligosaccharides development CDMOs reached the clinic before a detailed structure-activity relationship is carried out. For top hexa decamer oligosaccharides development CDMOs, Heparin is the key example of a major carbohydrate-based molecule, which has been developed for Oligosaccharides Development use in anti-coagulant therapies. Low molecular weight heparins (eg. Certoparin, Dalteparin) and various derivatives (Fondaparinux – fully synthetic) have Polysaccharides development CDMOs to improve efficacy of Polysaccharides API development CDMOs under clinical trials for non-thrombotic/vascular applications (eg. Certoparin for inflammatory aspects of Alzheimer’s disease). It is only comparatively recently that the anti-inflammatory properties of heparin have been discovered. Cyclodextrins CyDs are used in top Oligosaccharides Development CDMOs as functional excipients that form dynamic inclusion complexes in solution with APIs. Small quantities of water soluble polymers e.g. polyvinylpyrollidone (PVP) can enhance the efficiency of the complexation process facilitating reduction of the levels of CyD required.